Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.48T |
| Revenue (ttm) | 803.02B |
| Net Income (ttm) | 50.33B |
| Shares Out | 281.89M |
| EPS (ttm) | 178.19 |
| PE Ratio | 29.45 |
| Forward PE | 38.31 |
| Dividend | 160.00 (3.05%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | 1,673,500 |
| Average Volume | 1,690,870 |
| Open | 5,283.00 |
| Previous Close | 5,183.00 |
| Day's Range | 5,215.00 - 5,283.00 |
| 52-Week Range | 3,463.00 - 5,945.00 |
| Beta | -0.20 |
| RSI | 71.65 |
| Earnings Date | Nov 5, 2025 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1); Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Methycobal for the treatment of peripheral neur... [Read more]
Full Company ProfileFinancial Performance
In 2024, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.
Financial StatementsNews
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 TOKYO , Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd.
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data...
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. ...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK⢠(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Diseas...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive...
US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option f...
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment
Biogen and Eisai won Food and Drug Administration approval of an at-home shot version of their Alzheimer's treatment Leqembi.
Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news
Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news
Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease
Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation
Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wedne...
"URECE" (Dotinurad) Launched in China as a treatment for Gout
TOKYO, July 14, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has launched "URECE" (brand name in China: "Youlesi", generic name: dot...
Eisai: Leqembi Approved In EU (Rating Downgrade)
Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript
Eisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Eisai Co., Ltd.
Eisai GAAP EPS of ¥163.76, revenue of ¥789.4B; initiates FY outlook
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
The European Commission (EC) on Tuesday approved Eisai Co., Ltd. (OTC: ESALY) and Biogen Inc.’s (NASDAQ: BIIB) amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) , The Commission said it gran...
Biogen/ Eisai win EU approval for Alzheimer’s therapy
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.